This study combined data from a randomized, double‐blind, placebo‐controlled trial and information on GLP‐1 RA exposure and subsequent dementia diagnosis in type 2 diabetes patients, integrating findings from three randomized, double‐blind, placebo‐controlled cardiovascular outcomes trials involving 15,820 patients. The gene discussed is GLP1R; the disease is dementia.